NGeneBio Appoints New Chief Data Officer to Accelerate Genomic Data Business Expansion
Dr. Jenny Song, Expert in Gene Therapy and Drug Development Who Participated in the Development of Luxturna, Joins NGeneBio
Strengthening Data Business Strategy Based on Experience in Gene Therapy and Drug Development
Plans to Build Collaboration Models with Pharmaceutical and Biotechnology Companies Utilizing Genomic Data
NGeneBio, an AI precision medicine company, announced on June 15 that it has appointed Dr. Jenny Song as Chief Data Officer (CDO) to expand its genomic data business.
With the establishment of the new CDO position, NGeneBio plans to leverage its accumulated genomic data, based on its network of medical institutions, to expand its data business targeting pharmaceutical and biotechnology companies.
CDO Song holds a Ph.D. in Life Sciences from KAIST and is an expert with research and business development experience in gene therapy and new drug development. She has been involved in the entire process of developing adeno-associated virus (AAV) gene therapies and mRNA therapeutics, and participated in the development of the hereditary blindness treatment 'Luxturna'.
Afterward, she was responsible for establishing mRNA and gene therapy development strategies and technology commercialization at the Mogam Institute for Biomedical Research and GC Biopharma, accumulating business development experience through open innovation and licensing.
NGeneBio plans to build data business models that go beyond the collection and analysis of genomic data, enabling their use in research and new drug development processes, with CDO Song at the center. The company also aims to strengthen its data-driven precision medicine business by expanding collaborations with domestic and global pharmaceutical and biotechnology companies.
Hot Picks Today
Karina Fetches 6.7 Billion Won, Lives Under 24-Hour Armed Guard... World's Most Expensive Cow in the Spotlight
- "If It Breaks, That's It": Chaos Among Samsung and SK hynix Consumers... Soaring SSD Prices Mean "No Replacement, Only Refund at Original Price"
- "I'll Pay with Both Shares and Cash" vs "Cash Only"... Why Chey Taewon Filed a Further Appeal After Careful Deliberation
- Yu In-chon: "Even Sadder Than Last Year"...Bicycle Pilgrimage to Mark Brother's First Anniversary
- Do Night Runners Need Sunscreen? MFDS Says "UV from Streetlights Has Minimal Impact"
CDO Jenny Song stated, "I will establish data business models that researchers and pharmaceutical companies can actually use in the research and development process, and enhance the value of utilizing genomic data."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
